Hangzhou Tigermed Consulting Co Ltd (3347.HK)
Company Info
Highlights
HK$39.69B
HK$0.39
63.57
HK$6.51B
HK$2.08B
HK$22.30 - HK$58.80
HK$37.20
Share Price Chart
Loading data...
Compare to other instruments
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
Performance Chart
Loading data...
Returns By Period
Hangzhou Tigermed Consulting Co Ltd (3347.HK) returned -13.31% year-to-date (YTD) and -24.07% over the past 12 months.
3347.HK
-13.31%
3.69%
-29.46%
-24.07%
N/A
N/A
^GSPC (Benchmark)
-3.77%
7.44%
-5.60%
8.37%
14.12%
10.46%
Monthly Returns
The table below presents the monthly returns of 3347.HK, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | -8.77% | 20.46% | -8.42% | -13.71% | -0.19% | -13.31% | |||||||
| 2024 | -30.83% | 11.45% | 8.62% | 17.40% | -3.68% | -14.52% | 8.70% | -1.83% | 36.16% | -12.34% | -4.13% | -8.61% | -9.69% |
| 2023 | 13.64% | -12.15% | -18.16% | -11.67% | -8.93% | -23.94% | 12.88% | -15.18% | -3.86% | 6.93% | -6.26% | -14.20% | -60.42% |
| 2022 | -18.03% | 7.83% | 9.03% | -18.87% | -1.47% | 19.82% | -10.31% | -4.00% | -18.50% | -16.18% | 38.14% | 22.39% | -8.21% |
| 2021 | -4.05% | -11.02% | 1.25% | -0.72% | 5.87% | 12.90% | -17.25% | -8.37% | 20.07% | -8.45% | -18.06% | -20.35% | -44.20% |
| 2020 | 12.00% | -13.00% | 12.77% | 4.82% | 36.25% | 56.93% |
Risk-Adjusted Performance
Risk-Adjusted Performance Rank
The current rank of 3347.HK is 44, indicating average performance compared to other stocks on our website. Here’s a breakdown of how it compares using common performance measures.
Risk-Adjusted Performance Indicators
The charts below present risk-adjusted performance metrics for Hangzhou Tigermed Consulting Co Ltd (3347.HK) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.
Loading data...
Dividends
Dividend History
Hangzhou Tigermed Consulting Co Ltd provided a 4.46% dividend yield over the last twelve months, with an annual payout of HK$1.19 per share. The company has been increasing its dividends for 3 consecutive years.
| Period | TTM | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Dividend | HK$1.19 | HK$1.19 | HK$0.62 | HK$0.58 | HK$0.36 |
Dividend yield | 4.46% | 3.87% | 1.74% | 0.64% | 0.37% |
Monthly Dividends
The table displays the monthly dividend distributions for Hangzhou Tigermed Consulting Co Ltd. The dividends shown in the table have been adjusted to account for any splits that may have occurred.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | |||||||
| 2024 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.57 | HK$0.62 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$1.19 |
| 2023 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.62 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.62 |
| 2022 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.58 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.58 |
| 2021 | HK$0.36 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.36 |
Dividend Yield & Payout
Dividend Yield
Hangzhou Tigermed Consulting Co Ltd has a dividend yield of 4.46%, which is quite average when compared to the overall market.
Payout Ratio
Hangzhou Tigermed Consulting Co Ltd has a payout ratio of 3.09%, which is below the market average. This means Hangzhou Tigermed Consulting Co Ltd returns a smaller proportion of its earnings to shareholders as dividends, suggesting it retains a higher portion for reinvestment, growth, or debt payment.
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading data...
Worst Drawdowns
The table below displays the maximum drawdowns of the Hangzhou Tigermed Consulting Co Ltd. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Hangzhou Tigermed Consulting Co Ltd was 88.05%, occurring on Feb 5, 2024. The portfolio has not yet recovered.
The current Hangzhou Tigermed Consulting Co Ltd drawdown is 85.87%.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -88.05% | Jan 6, 2021 | 759 | Feb 5, 2024 | — | — | — |
| -13.95% | Sep 1, 2020 | 6 | Sep 8, 2020 | 27 | Oct 20, 2020 | 33 |
| -11.82% | Nov 18, 2020 | 9 | Nov 30, 2020 | 4 | Dec 4, 2020 | 13 |
| -6.58% | Nov 10, 2020 | 2 | Nov 11, 2020 | 2 | Nov 13, 2020 | 4 |
| -3.8% | Aug 10, 2020 | 3 | Aug 12, 2020 | 8 | Aug 24, 2020 | 11 |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading data...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Hangzhou Tigermed Consulting Co Ltd over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Earnings Per Share
The chart presents the Earnings Per Share (EPS) performance of Hangzhou Tigermed Consulting Co Ltd, comparing actual results with analytics estimates. The company has exceeded analyst expectations for EPS in the past quarter, achieving a 6.9% positive surprise.
Valuation
The Valuation section provides an overview of how Hangzhou Tigermed Consulting Co Ltd is priced in the market compared to other companies in the Diagnostics & Research industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PE Ratio
The chart displays the Price-to-Earnings (P/E) ratio for 3347.HK, comparing it with other companies in the Diagnostics & Research industry. Currently, 3347.HK has a P/E ratio of 63.6. This P/E ratio is significantly higher than those of industry peers. This could indicate that the stock is overvalued or that investors expect strong future growth.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for 3347.HK relative to other companies in the Diagnostics & Research industry. Currently, 3347.HK has a P/S ratio of 6.0. This P/S ratio is high relative to other companies in the industry. It could mean the stock is overvalued, or that investors expect strong future growth and profitability.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for 3347.HK in comparison with other companies in the Diagnostics & Research industry. Currently, 3347.HK has a P/B value of 1.0. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |